Viewing Study NCT05691712



Ignite Creation Date: 2024-05-06 @ 6:32 PM
Last Modification Date: 2024-10-26 @ 2:49 PM
Study NCT ID: NCT05691712
Status: COMPLETED
Last Update Posted: 2024-05-29
First Post: 2023-01-11

Brief Title: A Study of Tirzepatide LY3298176 in Chinese Participants With Type 2 Diabetes
Sponsor: Eli Lilly and Company
Organization: Eli Lilly and Company

Study Overview

Official Title: A Randomized Phase 3 Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes
Status: COMPLETED
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SURPASS-CN-INS
Brief Summary: The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
I8F-MC-GPIM OTHER Eli Lilly and Company None